Priority setting for pharmaceuticals: The use of health economic evidence by reimbursement and clinical guidance committees

Author： Anell Anders  

Publisher： Springer Publishing Company

ISSN： 1618-7598

Source： The European Journal of Health Economics, Vol.5, Iss.1, 2004-02, pp. : 28-35

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Telaprevir: evidence and guidance for use in clinical practice

By Lewis Heather   Foster Graham  

Clinical Practice, Vol. 10, Iss. 3, 2013-05 ,pp. : 265-273

Future Medicine

Access to resources Recommend Favorite

Priority setting for health in emerging markets

By Glassman Amanda   Giedion Ursula   McQueston Kate  

Journal of Comparative Effectiveness Research, Vol. 2, Iss. 3, 2013-05 ,pp. : 283-291

Future Medicine

Access to resources Recommend Favorite

Reviewing current clinical trials in women's health raises questions about research priority‐setting in low‐income countries

By  

BJOG : AN INTERNATIONAL JOURNAL OF OBSTETRICS & GYNAECOLOGY, Vol. 122, Iss. 2, 2015-01 ,pp. : 200-200

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pricing and reimbursement of pharmaceuticals in Italy

By Folino-Gallo Pietro  

The European Journal of Health Economics, Vol. 9, Iss. 3, 2008-08 ,pp. : 305-310

Springer Publishing Company

Access to resources Recommend Favorite

Objectivity in Priority Setting Tools in Reproductive Health: Context and the DALY

By Allotey P.A.   Reidpath D.D.  

Reproductive Health Matters, Vol. 10, Iss. 20, 2002-11 ,pp. : 38-46

Elsevier

Access to resources Recommend Favorite